<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006738</article-id><article-id pub-id-type="pmc">PMC11860627</article-id><article-id pub-id-type="doi">10.3390/vaccines13020192</article-id><article-id pub-id-type="publisher-id">vaccines-13-00192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults &#x02265;50 Years of Age</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Omole</surname><given-names>Tosin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00192" ref-type="corresp">*</xref><xref rid="fn1-vaccines-13-00192" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Pelayo</surname><given-names>Enrique</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-vaccines-13-00192" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0954-7646</contrib-id><name><surname>Weinberg</surname><given-names>Aaron S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-vaccines-13-00192" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Chalkias</surname><given-names>Spyros</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-vaccines-13-00192" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Endale</surname><given-names>Zelalem</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-vaccines-13-00192" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Tamms</surname><given-names>Gretchen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Sterling</surname><given-names>Tina M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Good</surname><given-names>Lori</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shekar</surname><given-names>Tulin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Morgan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Banniettis</surname><given-names>Natalie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6671-0115</contrib-id><name><surname>Buchwald</surname><given-names>Ulrike K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6165-197X</contrib-id><name><surname>Esteves-Jaramillo</surname><given-names>Alejandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-13-00192" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Casuccio</surname><given-names>Alessandra</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00192"><label>1</label>Merck &#x00026; Co., Inc., Rahway, NJ 07065, USA; <email>gretchen_tamms@merck.com</email> (G.T.); <email>tina_sterling@merck.com</email> (T.M.S.); <email>lori_good@merck.com</email> (L.G.); <email>tulin.shekar@merck.com</email> (T.S.); <email>morgan.johnson@merck.com</email> (M.J.); <email>natalie.banniettis@merck.com</email> (N.B.); <email>ulrike.buchwald@merck.com</email> (U.K.B.); <email>alex.esteves@merck.com</email> (A.E.-J.)</aff><aff id="af2-vaccines-13-00192"><label>2</label>Advanced Medical Research Institute, Miami, FL 33174, USA; <email>epelayomd@amriresearch.com</email></aff><aff id="af3-vaccines-13-00192"><label>3</label>Carbon Health, North Hollywood, CA 91606, USA; <email>aaron@carbonhealth.com</email></aff><aff id="af4-vaccines-13-00192"><label>4</label>Moderna, Cambridge, MA 02142, USA; <email>spyros.chalkias@modernatx.com</email> (S.C.); <email>zelalem.endale@modernatx.com</email> (Z.E.)</aff><author-notes><corresp id="c1-vaccines-13-00192"><label>*</label>Correspondence: <email>tosin.omole@merck.com</email></corresp><fn id="fn1-vaccines-13-00192"><label>&#x02020;</label><p>Current address: Merck &#x00026; Co., Inc., 351 N Sumneytown Pike, North Wales, PA 19454, USA.</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>192</elocation-id><history><date date-type="received"><day>02</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>04</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: <italic toggle="yes">Streptococcus pneumoniae</italic> with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults. However, vaccination can be an effective preventative measure. This Phase 3 study (NCT05158140) assessed the immunogenicity and safety of co-administering the SARS-CoV-2 vaccine mRNA-1273 with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or the 15-valent pneumococcal conjugate vaccine (PCV15). Methods: Participants were healthy adults &#x02265;50 years of age who had previously received a two-dose primary series of mRNA-1273 &#x02265;5 months before the first study visit and may have received a booster dose of mRNA-1273 &#x02265;4 months prior to the first study visit. Participants were randomized (1:1:1:1) to receive mRNA-1273 concomitantly with PPSV23 or PCV15 on Day 1 followed by placebo on Day 30, or sequentially with mRNA-1273 and placebo on Day 1 and PPSV23 or PCV15 on Day 30. The primary study endpoints were pneumococcal-serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) and SARS-CoV-2-specific binding antibody GMTs at 30 days after vaccination, as well as safety and tolerability following vaccination. Results: In total, 850 adults participated in the study. Serotype-specific OPA GMTs at 30 days post-vaccination with PPSV23 or PCV15 were generally comparable between the concomitant and sequential groups. SARS-CoV-2-specific GMTs increased in all groups from pre-vaccination to 30 days post-vaccination with mRNA-1273, with a consistent response between concomitant and sequential groups. Safety profiles were comparable across study groups. Conclusions: Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults &#x02265;50 years of age was immunogenic and well tolerated.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>immunogenicity</kwd><kwd>pneumococcal</kwd><kwd>safety</kwd><kwd>tolerability</kwd><kwd>vaccination</kwd><kwd>vaccine</kwd></kwd-group><funding-group><award-group><funding-source>Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, New Jersey, USA</funding-source></award-group><funding-statement>This study was funded by Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, NJ, USA.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00192"><title>1. Introduction</title><p>The burden of disease caused by <italic toggle="yes">Streptococcus pneumoniae</italic> is high among adults &#x02265;50 years of age and is highest in older adults &#x02265;65 years of age [<xref rid="B1-vaccines-13-00192" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00192" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00192" ref-type="bibr">3</xref>]. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which results in coronavirus disease 2019 (COVID-19), can predispose individuals to bacterial infections and diseases, such as pneumococcal disease (PD) [<xref rid="B4-vaccines-13-00192" ref-type="bibr">4</xref>]. Pneumococcal infection can occur at the same time as an infection with SARS-CoV-2 (co-infection) or can occur afterwards as a secondary infection [<xref rid="B4-vaccines-13-00192" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-13-00192" ref-type="bibr">5</xref>]; both have been associated with increased mortality compared with invasive PD (IPD) or COVID-19 alone [<xref rid="B6-vaccines-13-00192" ref-type="bibr">6</xref>]. This increased mortality can often be observed among at-risk populations, such as older adults or those with certain underlying chronic medical conditions [<xref rid="B7-vaccines-13-00192" ref-type="bibr">7</xref>]. In addition, studies have shown that individuals who experience milder symptoms of SARS-CoV-2 infection, such as fever, mild or moderate coughing, and shortness of breath, can have higher carriage rates of <italic toggle="yes">S. pneumoniae</italic> than those not infected with SARS-CoV-2 [<xref rid="B8-vaccines-13-00192" ref-type="bibr">8</xref>]. Furthermore, infection with SARS-CoV-2 can compromise the immune system and is considered a primary risk factor for IPD [<xref rid="B8-vaccines-13-00192" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00192" ref-type="bibr">9</xref>].</p><p>Pneumococcal polysaccharide and conjugate vaccines with varying serotype coverage are recommended by the US Centers for Disease Control and Prevention (CDC) for children &#x02264;5 years of age, adults &#x02265;50 years of age, and children and adults at increased risk of PD [<xref rid="B10-vaccines-13-00192" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00192" ref-type="bibr">11</xref>]. Pneumococcal vaccines have a long history of use and have been demonstrated to be immunogenic and effective, with a favorable safety profile [<xref rid="B12-vaccines-13-00192" ref-type="bibr">12</xref>]. These vaccines are the mainstay of disease prevention and have led to a substantial decrease in cases of IPD, respiratory disease burden, and healthcare utilization [<xref rid="B13-vaccines-13-00192" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00192" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00192" ref-type="bibr">15</xref>]. A widely used pneumococcal vaccine is the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax<sup>&#x000ae;</sup> 23, Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, NJ, USA [MSD]). PPSV23 is indicated for the prevention of PD in older adults &#x02265;50 years of age and individuals &#x02265;2 years of age with certain medical conditions that can lead to an increased risk of PD. PPSV23 contains 23 different serotypes of <italic toggle="yes">S. pneumoniae</italic> (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) [<xref rid="B13-vaccines-13-00192" ref-type="bibr">13</xref>,<xref rid="B16-vaccines-13-00192" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-13-00192" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00192" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00192" ref-type="bibr">19</xref>]. A 15-valent pneumococcal conjugate vaccine (PCV15; VAXNEUVANCE&#x02122;, MSD) is also available in many countries and is indicated in individuals &#x02265;6 weeks of age for the prevention of IPD and pneumonia, and in individuals 6 weeks to &#x02264;18 years of age for acute otitis media, caused by <italic toggle="yes">S. pneumoniae</italic> serotypes contained in the vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) [<xref rid="B15-vaccines-13-00192" ref-type="bibr">15</xref>]. The CDC recommends that, in adults, administration of PCV15 should be followed by a single dose of PPSV23 1 year later [<xref rid="B10-vaccines-13-00192" ref-type="bibr">10</xref>,<xref rid="B20-vaccines-13-00192" ref-type="bibr">20</xref>].</p><p>After the novel SARS-CoV-2 virus was identified in 2019, an urgent need arose for vaccines to curb the rapidly spreading pandemic, reduce severe illness and mortality, and address the global health crisis [<xref rid="B21-vaccines-13-00192" ref-type="bibr">21</xref>]. The mRNA-1273 COVID-19 vaccine (SPIKEVAX<sup>&#x000ae;</sup>, Moderna Inc., Cambridge, MA, USA) received emergency use authorization (EUA) from the US Food and Drug Administration on 18 December 2020, for the immunization of adults &#x02265;18 years of age. Almost a year later, the EUA was amended to include the use of an mRNA-1273 booster dose, administered &#x02265;6 months after completion of the primary series [<xref rid="B22-vaccines-13-00192" ref-type="bibr">22</xref>]. mRNA-1273 is a nucleoside-modified messenger RNA (mRNA) vaccine containing single mRNAs encoding the prefusion-stabilized spike glycoprotein of ancestral SARS-CoV-2 (Wuhan-Hu-1). During the study period, the monovalent mRNA-1273 was indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals &#x02265;12 years of age (SPIKEVAX<sup>&#x000ae;</sup> [COVID-19 Vaccine, mRNA, 2024&#x02013;2025 Formula], Moderna TX, Cambridge, MA, USA) [<xref rid="B23-vaccines-13-00192" ref-type="bibr">23</xref>].</p><p>The US Advisory Committee on Immunization Practices (ACIP) recommends that SARS-CoV-2 vaccines be co-administered with other vaccines [<xref rid="B24-vaccines-13-00192" ref-type="bibr">24</xref>]. The feasibility of co-administration of vaccines in older adults has been previously demonstrated [<xref rid="B25-vaccines-13-00192" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-13-00192" ref-type="bibr">26</xref>]. Co-administration of vaccines helps increase vaccination coverage by reducing the number of vaccination visits, lowering costs, minimizing missed opportunities, improving compliance, and ensuring timely vaccine administration [<xref rid="B27-vaccines-13-00192" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00192" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>]. In a meta-analysis of 17 studies, co-administration of influenza and pneumococcal vaccines resulted in an additional 24% reduction in pneumonia and an additional 28% reduction in deaths in older adults compared with pneumococcal vaccination alone [<xref rid="B30-vaccines-13-00192" ref-type="bibr">30</xref>]. Furthermore, in a study of US adults who had received 13-valent pneumococcal conjugate vaccine (Prevnar13<sup>&#x000ae;</sup>, Pfizer Inc., New York, NY, USA) with or without PPSV23, based on the intervals recommended in the 2015 ACIP guidelines for those &#x02265;65 years of age, pneumococcal vaccination was associated with a reduced risk of COVID-19 diagnosis, hospitalization, or fatal hospitalization [<xref rid="B31-vaccines-13-00192" ref-type="bibr">31</xref>].</p><p>This study was conducted to assess the safety, tolerability, and immunogenicity of mRNA-1273 administered concomitantly with a single dose of a pneumococcal vaccine (PPSV23 or PCV15), compared with sequential administration of the same vaccines, in healthy adults &#x02265;50 years of age.</p></sec><sec sec-type="methods" id="sec2-vaccines-13-00192"><title>2. Methods</title><p>This Phase 3, randomized, placebo-controlled, parallel-group, multicenter, double-blind study was conducted between 12 January 2022 and 27 October 2023, during the COVID-19 pandemic (Protocol V110-911; NCT05158140; <xref rid="vaccines-13-00192-f001" ref-type="fig">Figure 1</xref>). Participants were enrolled at 44 sites across the United States and Puerto Rico (<xref rid="app1-vaccines-13-00192" ref-type="app">Table S1</xref>).</p><sec sec-type="subjects" id="sec2dot1-vaccines-13-00192"><title>2.1. Participants, Randomization, and Blinding</title><p>Eligible participants were adults &#x02265;50 years of age who had previously completed a two-dose primary series of mRNA-1273 &#x02265;5 months before the receipt of the study vaccine at the first study visit. Participants with historic SARS-CoV-2 infection and those who had received a prior booster dose of mRNA-1273 were also included. The study was conducted amidst an evolving SARS-CoV-2 vaccine landscape and the protocol was amended to reflect changes in vaccine recommendations. Participants were excluded if they had a current SARS-CoV-2 infection, a known history of SARS-CoV-2 infection &#x0003c;3 months before receipt of the study vaccine at the first study visit, or if they had a history of myocarditis and/or pericarditis. Participants with underlying chronic conditions were assessed by the investigator to be in a stable condition. Detailed inclusion and exclusion criteria are provided in <xref rid="app1-vaccines-13-00192" ref-type="app">Table S2</xref>.</p><p>Participants were randomly assigned in a 1:1:1:1 ratio via a centralized interactive response technology system. Participants who received mRNA-1273 (50 &#x000b5;g/0.25 mL) concomitantly with either PPSV23 (refer to product label for dosage) or PCV15 (refer to product label for dosage) at the first study visit, followed by placebo at Visit 3, were in the PPSV23 concomitant group or PCV15 concomitant group, respectively. Participants who received mRNA-1273 with placebo at the first study visit, followed by either PPSV23 or PCV15 at Visit 3, were in the PPSV23 sequential group or PCV15 sequential group, respectively (<xref rid="vaccines-13-00192-f001" ref-type="fig">Figure 1</xref>). Stratification factors included age (50&#x02013;64 years, 65&#x02013;74 years, and &#x02265;75 years of age), history of pneumococcal vaccination (yes or no), receipt of prior mRNA-1273 booster dose following the two-dose primary series (yes or no), and history of prior SARS-CoV-2 infection (yes or no).</p><p>PPSV23, PCV15, and placebo were prepared and administered by an unblinded pharmacist or qualified personnel. The participant, investigator, and other personnel involved in study conduct or clinical evaluation were blinded. mRNA-1273 was provided open-label and was also prepared and administered by unblinded personnel.</p><p>This study was conducted in accordance with principles of Good Clinical Practice guidelines and was approved by the appropriate institutional review boards and regulatory agencies [<xref rid="B32-vaccines-13-00192" ref-type="bibr">32</xref>]. The institutional review board approved the protocol, protocol amendments, and informed consent form. All participants provided written informed consent before enrollment. The study protocol and statistical analysis plan are available online [<xref rid="B33-vaccines-13-00192" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot2-vaccines-13-00192"><title>2.2. Immunogenicity Assessments</title><p>There were two primary immunogenicity endpoints in this study. The first was to evaluate the pneumococcal-serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 30 days post-vaccination with PPSV23 or PCV15 in each of the four groups. The other primary endpoint was to evaluate SARS-CoV-2-specific binding antibody GMTs at 30 days post-vaccination with mRNA-1273 in each of the four groups. Data from both sequential groups were combined for the SARS-CoV-2 immunogenicity analysis.</p><p>Secondary endpoints included assessing the serotype-specific geometric mean fold rises (GMFRs) and the proportions of participants with a &#x02265;4-fold rise from baseline (pre-vaccination) to 30 days post-vaccination for OPA responses in each group. For SARS-CoV-2-specific binding antibody responses, the GMFRs and proportions of participants with a &#x02265;4-fold rise from baseline to 30 days post-vaccination with mRNA-1273 were assessed in each group. The immunogenicity analyses were based on the per-protocol population, which comprised all randomized participants without deviations from the protocol that could have substantially affected immunogenicity measurements.</p><p>Immune responses were measured for the PCV15 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) in a validated multiplex opsonophagocytic assay. This assay measured 14 of the 23 pneumococcal serotypes in PPSV23 (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F). A validated ligand-binding assay specific to the SARS-CoV-2 spike protein was used to measure vaccine-induced responses to mRNA-1273.</p></sec><sec id="sec2dot3-vaccines-13-00192"><title>2.3. Safety Assessments</title><p>The primary safety objective was the assessment of safety and tolerability of a booster dose of mRNA-1273 administered concomitantly or sequentially with a single dose of pneumococcal vaccine (PPSV23 or PCV15). Primary safety endpoints included solicited injection-site adverse events (AEs), solicited systemic AEs, and vaccine-related serious AEs (SAEs). Participants were followed for 7 days post-vaccination for the number of solicited injection-site and systemic AEs. All solicited injection-site AEs (from Day 1 through Day 7 post-vaccination) were considered to be vaccine-related. All SAEs and AEs of special interest (AESIs), discontinuations of study intervention due to an AE, and deaths were collected from Day 1 through to study completion. AESIs were consistent with the regulatory guidance for the safety evaluation of mRNA-1273 and are listed in <xref rid="app1-vaccines-13-00192" ref-type="app">Table S3</xref>. Post-vaccination body temperature measurement was the only vital sign collected, and the temperatures were recorded after each vaccination on Days 1&#x02013;7 using an electronic vaccination report card. All AEs and SAEs were assessed for overall intensity grade by the investigator and were recorded along with AE duration in days. Instances of injection-site erythema and swelling occurring on Days 1&#x02013;7 were categorized as mild (2.5&#x02013;5.0 cm), moderate (5.1&#x02013;10.0 cm), or severe (&#x0003e;10 cm). Safety analyses were based on the all-participants-as-treated population, which included all randomized participants who received at least one dose of the study vaccine.</p></sec><sec id="sec2dot4-vaccines-13-00192"><title>2.4. Statistical Analyses</title><p>On 31 August 2022, EUA for monovalent COVID-19 vaccines was withdrawn in favor of bivalent COVID-19 vaccine boosters. This change resulted in prematurely concluding enrollment [<xref rid="B34-vaccines-13-00192" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00192" ref-type="bibr">35</xref>]. Therefore, the planned enrollment of 1300 participants was changed to approximately 850 participants. Owing to this change, the study was descriptive in nature and not based on formal statistical hypothesis testing.</p><p>Evaluation of the OPA GMTs and the binding antibody GMTs at 30 days post-vaccination in each group included descriptive summaries and within-group 95% confidence intervals (CIs) for each vaccination group. The point estimates were calculated by exponentiating the estimates of the mean of the natural log values, and the within-group CIs were derived by exponentiating the CIs of the mean of the natural log values based on the t-distribution.</p><p>Reverse cumulative distribution curves were used to show the distribution of serotype-specific OPA titers and SARS-CoV-2-specific binding antibody titers for PPSV23 and PCV15 concomitant and sequential groups.</p><p>The safety analysis followed a tiered approach. For the Tier 2 safety endpoints, point estimates, with corresponding within-group 95% CIs based on the exact binomial method proposed by Clopper and Pearson [<xref rid="B36-vaccines-13-00192" ref-type="bibr">36</xref>], were provided for the proportions of participants with events following any vaccination. Clinical laboratory evaluations were not prespecified for this study. The Medical Dictionary for Regulatory Activities (MedDRA) version 26.0 was used for this study.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00192"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00192"><title>3.1. Study Population</title><p>A total of 850 participants were randomized: 212 participants in the PPSV23 sequential group, 210 participants in the PCV15 sequential group, and 214 participants in each of the PPSV23 and PCV15 concomitant groups (<xref rid="vaccines-13-00192-f002" ref-type="fig">Figure 2</xref>). Most randomized participants received at least one dose of study vaccine and completed the study (&#x02265;93.9%). The most common reasons for discontinuing the study across all groups were participant withdrawal (2.4%) and loss to follow-up (1.9%). Most randomized participants were included in the immunogenicity analyses; in the PPSV23 sequential and PCV15 sequential groups, &#x02265;87.3% and &#x02265;87.6% were included at one or more timepoints, respectively. In addition, &#x02265;85.8% and &#x02265;87.6% were included for both baseline and post-vaccination timepoints, respectively.</p><p>Baseline demographic characteristics were comparable across all groups (<xref rid="vaccines-13-00192-t001" ref-type="table">Table 1</xref> and <xref rid="app1-vaccines-13-00192" ref-type="app">Table S4</xref>). The mean age of participants was 60.4 years, with 73.4% of participants being in the 50&#x02013;64-years-old age category; 56.9% were female, 77.9% were white, and 43.2% were of Hispanic or Latino ethnicity. Participants across all four groups generally had comparable pre-existing medical conditions (<xref rid="app1-vaccines-13-00192" ref-type="app">Table S5</xref>). No participants had a prior history of infection with SARS-CoV-2.</p></sec><sec id="sec3dot2-vaccines-13-00192"><title>3.2. Immunogenicity</title><p>Serotype-specific OPA GMTs at 30 days post-vaccination were generally comparable between the PPSV23 concomitant and sequential groups and PCV15 concomitant and sequential groups (<xref rid="vaccines-13-00192-t002" ref-type="table">Table 2</xref>). A trend was observed in which the serotype-specific OPA GMTs for some serotypes were numerically lower in the PPSV23 and PCV15 concomitant groups compared with the PPSV23 or PCV15 sequential groups, respectively. The distribution of serotype-specific OPA titers was generally comparable between all groups, as demonstrated by the reverse cumulative distribution curves (<xref rid="app1-vaccines-13-00192" ref-type="app">Figures S1 and S2</xref>).</p><p>The observed serotype-specific GMFRs and the proportions of participants with a &#x02265;4-fold rise in GMFRs from baseline to 30 days post-vaccination with PPSV23 and PCV15 were generally comparable for most serotypes in the PPSV23 and PCV15 concomitant groups compared with the PPSV23 and PCV15 sequential groups (<xref rid="app1-vaccines-13-00192" ref-type="app">Tables S6 and S7</xref>).</p><p>SARS-CoV-2-specific binding antibody GMTs at 30 days post-vaccination with mRNA-1273 were numerically lower in the PPSV23 and PCV15 concomitant groups compared with the PPSV23 and PCV15 sequential groups (<xref rid="vaccines-13-00192-t003" ref-type="table">Table 3</xref>). The distribution of SARS-CoV-2-specific binding antibody titers was similar between the PPSV23 sequential and concomitant groups, as well as the PCV15 sequential and concomitant groups, as shown by reverse cumulative distribution curves (<xref rid="app1-vaccines-13-00192" ref-type="app">Figure S3</xref>).</p><p>The observed SARS-CoV-2 binding antibody titer GMFRs and the proportions of participants with a &#x02265;4-fold rise in GMFRs from baseline to 30 days post-vaccination with mRNA-1273 were generally comparable in the PPSV23 and PCV15 concomitant groups compared with the PPSV23 and PCV15 sequential groups (<xref rid="app1-vaccines-13-00192" ref-type="app">Tables S6 and S7</xref>).</p></sec><sec id="sec3dot3-vaccines-13-00192"><title>3.3. Safety</title><p>The majority of participants in the PPSV23 groups (81.4%) and PCV15 groups (81.1%) reported at least one AE following any vaccination (<xref rid="vaccines-13-00192-t004" ref-type="table">Table 4</xref>). The proportions of participants with AEs, including injection-site AEs, systemic AEs, vaccine-related AEs, and SAEs, were generally comparable across all groups. Post-vaccination, the most common AEs in the PPSV23 and PCV15 groups were solicited AEs (&#x02265;79% and &#x02265;78%, respectively; <xref rid="vaccines-13-00192-f003" ref-type="fig">Figure 3</xref>), which were similar in frequency in all groups, and most events were classified as mild (Grade 1) or moderate (Grade 2) in intensity. The incidence of severe solicited AEs (Grade 3) was low in the PPSV23 and PCV15 groups (&#x02264;4.3% and &#x02264;5.8%, respectively). Injection-site pain was the most frequently reported solicited AE in the PPSV23 and PCV15 groups (74.6% and 73.9%, respectively; <xref rid="app1-vaccines-13-00192" ref-type="app">Table S8</xref>).</p><p>The proportions of participants with systemic AEs were generally comparable between the PPSV23 concomitant (57.9%) and sequential (54.2%) groups, and between the PCV15 concomitant (53.1%) and sequential (54.2%) groups. The proportions of participants with vaccine-related systemic AEs were similar between the PPSV23 concomitant (55.6%) and sequential (51.2%) groups, and between the PCV15 concomitant (53.1%) and sequential (59.6%) groups, following any vaccination. The incidence of SAEs was low in both the PPSV23 (&#x0003c;1%) and PCV15 (&#x0003c;3%) groups, and none were considered by the investigator to be related to study vaccine.</p><p>One participant (0.2%) discontinued from the PPSV23 concomitant group due to a non-serious AE of injection-site induration, which was considered by the investigator to be vaccine-related. Two (0.5%) participants (both from the PCV15 sequential group) discontinued due to SAEs, which were not considered by the investigator to be vaccine-related; one participant had an SAE of pancreatic carcinoma and the other had an SAE, which was also classified as an AESI, of cardiac arrest on Day 8, resulting in death. There were no AESIs or deaths due to AEs in the PPSV23 groups. The frequency of solicited maximum body temperature measurements was similar between the PPSV23 groups and the PCV15 groups, with &#x0003c;100.4 &#x000b0;F (38.0 &#x000b0;C) being reported in &#x0003e;94% of participants in each group.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00192"><title>4. Discussion</title><p>The results from this study support the co-administration of mRNA-1273 with either PPSV23 or PCV15. Serotype-specific OPA GMTs at 30 days post-vaccination were generally comparable when PPSV23 or PCV15 were administered concomitantly or sequentially with mRNA-1273. Concomitant administration of mRNA-1273 with either PPSV23 or PCV15 could alter antigen uptake and the function of antigen-presenting cells, potentially influencing the immunogenicity of one or both vaccines compared with administering mRNA-1273 alone [<xref rid="B37-vaccines-13-00192" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00192" ref-type="bibr">38</xref>]. The SARS-CoV-2 antibody responses were lower when mRNA-1273 was administered concomitantly with PPSV23 or PCV15, compared with mRNA-1273 + placebo. However, this difference is unlikely to be clinically meaningful, given the robust GMTs observed overall. Furthermore, reverse cumulative distribution curves for SARS-CoV-2 binding antibody titers, binding antibody GMFRs, and the proportions of participants with &#x02265;4-fold rises in binding antibody GMTs from baseline to 30 days post-vaccination with mRNA-1273 were generally comparable between the groups.</p><p>The safety results from this study showed that co-administration of PPSV23 or PCV15 with mRNA-1273 was well tolerated, and the safety profiles of concomitant administration were consistent with those of the individual vaccines, as observed in other studies [<xref rid="B39-vaccines-13-00192" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00192" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00192" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00192" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-13-00192" ref-type="bibr">43</xref>]. The overall proportions of participants with AEs were generally comparable between the groups.</p><p>Further evidence to support the feasibility and potential benefits of co-administration of a pneumococcal vaccine with a COVID-19 vaccine was demonstrated in a Phase 3 study [<xref rid="B44-vaccines-13-00192" ref-type="bibr">44</xref>]. The safety and immunogenicity profiles of concomitant administration of 20-valent pneumococcal conjugate vaccine (Prevnar20<sup>&#x000ae;</sup>, Pfizer Inc., New York, NY, USA) and BNT162b2 (Comirnaty<sup>&#x000ae;</sup>; Pfizer-BioNTech) were comparable to those observed when each vaccine was administered alone [<xref rid="B44-vaccines-13-00192" ref-type="bibr">44</xref>]. The co-administration of pneumococcal and COVID-19 vaccines could be a strategy to increase vaccination rates by maximizing opportunities to vaccinate populations at-risk and by helping to increase the likelihood that individuals are fully vaccinated at the appropriate age, ultimately having a positive impact on public health [<xref rid="B26-vaccines-13-00192" ref-type="bibr">26</xref>,<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00192" ref-type="bibr">30</xref>]. Several studies have assessed the co-administration of COVID-19 vaccines and influenza vaccines [<xref rid="B25-vaccines-13-00192" ref-type="bibr">25</xref>,<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>,<xref rid="B45-vaccines-13-00192" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00192" ref-type="bibr">46</xref>]. The studies reported no major safety issues associated with co-administration, and AEs were typically of mild or moderate severity and were self-limiting. Co-administration did not significantly affect the immunogenicity of either the influenza or COVID-19 vaccines [<xref rid="B25-vaccines-13-00192" ref-type="bibr">25</xref>,<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>,<xref rid="B45-vaccines-13-00192" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00192" ref-type="bibr">46</xref>]. A systematic literature review reported that, in studies that assessed the acceptability of co-administration, the majority of individuals expressed willingness to receive both vaccines [<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>]. This growing body of evidence supports the benefits of administering COVID-19 vaccines alongside other vaccines. Therefore, there is a strong rationale for raising awareness about the safety of vaccine co-administration, which could enhance compliance with vaccine recommendations [<xref rid="B27-vaccines-13-00192" ref-type="bibr">27</xref>]. Furthermore, concomitant administration of vaccines ensures that individuals facing challenges in accessing care receive full protection [<xref rid="B27-vaccines-13-00192" ref-type="bibr">27</xref>,<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>]. Co-administration decreases the number of consultations and avoids scheduling multiple vaccination appointments that can often be missed and lead to higher rates of attrition [<xref rid="B28-vaccines-13-00192" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-13-00192" ref-type="bibr">29</xref>].</p><p>The limitations of the study included that it was descriptive in nature and not based on formal statistical hypothesis testing, as enrollment closed early [<xref rid="B34-vaccines-13-00192" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00192" ref-type="bibr">35</xref>]. Although formal statistical comparisons were not made, serotype-specific OPA GMTs and SARS-CoV-2-specific GMTs for concomitant and sequential groups demonstrated generally comparable immunogenicity, with overlapping 95% CIs for most serotypes tested, suggesting limited changes in immunogenicity when administered concomitantly. While it is not expected that any numerical differences observed between groups are clinically meaningful, real-world evidence is required to confirm. As this study evaluated the original mRNA-1273 formulation, it is important to note the findings may not fully apply to the updated mRNA-1273 formulations or other pneumococcal vaccines not tested. However, clinical trial and safety surveillance data support the concomitant administration of pneumococcal vaccines with these updated formulations, showing comparable safety and immunologic profiles to the original mRNA-1273 vaccine [<xref rid="B47-vaccines-13-00192" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-13-00192" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-13-00192" ref-type="bibr">49</xref>]. Another limitation was that the study assessed individuals who previously received the mRNA-1273 vaccine, while, in practice, many individuals receive a mix of SARS-CoV-2 vaccines from different manufacturers. These factors restrict the generalizability of the findings to broader vaccine strategies [<xref rid="B30-vaccines-13-00192" ref-type="bibr">30</xref>,<xref rid="B50-vaccines-13-00192" ref-type="bibr">50</xref>].</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00192"><title>5. Conclusions</title><p>This study provides evidence that the co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults &#x02265;50 years of age is immunogenic, with a safety profile comparable to administering mRNA-1273 with a placebo. These results add to the growing evidence that COVID-19 vaccines have a good safety profile and are effective when administered concomitantly with other vaccines [<xref rid="B44-vaccines-13-00192" ref-type="bibr">44</xref>]. These findings may inform future vaccination recommendations or vaccination guidelines, enhance vaccine program implementation, and potentially help to increase coverage rates for other licensed vaccines.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank the participants, their families, and all investigators involved in this study. Medical writing support, including assisting authors with the development of the outline and initial draft and incorporation of comments, was provided by Sara Shaw, CMPP, and Lauren Moreton, MRes, and editorial support, including fact checking, referencing, figure preparation, formatting, proofreading, and submission, was provided by Ian Norton, all of Scion, a Division of Prime, London, UK, supported by Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, NJ, USA, according to Good Publication Practice guidelines (<uri xlink:href="https://www.acpjournals.org/doi/10.7326/M22-1460">https://www.acpjournals.org/doi/10.7326/M22-1460</uri>; accessed on 13 February 2025).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00192"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020192/s1">https://www.mdpi.com/article/10.3390/vaccines13020192/s1</uri>, Table S1: Investigators. The following investigators randomized at least one participant in the clinical study; Table S2: Eligibility criteria; Table S3: Definition of adverse events of special interest; Table S4: Baseline characteristics and demographics by strata; Table S5: Pre-existing medical conditions occurring in &#x02265;5% of participants (any group); Table S6: Secondary immunogenicity endpoint: Serotype-specific GMFRs and proportions of participants with &#x02265;4-fold rise for OPA responses at 30 days post-vaccination with PPSV23; Table S7: Secondary immunogenicity endpoints: GMFRs and proportions of participants with &#x02265;4-fold rise for OPA antibody responses at 30 days post-vaccination with PCV15; Table S8: Most frequently reported AEs (&#x02265;5% incidence in any group); Figure S1: Reverse cumulative distribution curve of OPA titers at baseline and 30 days post-vaccination in the PPSV23 groups; Figure S2: Reverse cumulative distribution curve of OPA titers at baseline and 30 days post-vaccination in the PCV15 groups; Figure S3: Reverse cumulative distribution curve of SARS-CoV-2-specific binding titers at baseline and 30 days post-vaccination with mRNA-1273.</p><supplementary-material id="vaccines-13-00192-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00192-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>T.O., S.C., Z.E., G.T., T.M.S., T.S., N.B. and U.K.B. were responsible for the conception, design, and planning of the study. E.P., T.S. and M.J. were responsible for the acquisition of data. M.J., N.B. and A.E.-J. were responsible for analysis of data. A.S.W., L.G., T.S., M.J., N.B., U.K.B. and A.E.-J. were responsible for interpretation of results. T.S., M.J., N.B., U.K.B. and A.E.-J. were responsible for original draft preparation. E.P., A.S.W., S.C., Z.E., G.T., T.M.S., L.G., T.S., M.J., N.B., U.K.B. and A.E.-J. were responsible for critically reviewing and revising the manuscript for important intellectual content. A.E.-J. was responsible for preparation and creation of the published work, specifically visualization/data presentation. T.O., A.S.W., G.T., T.M.S., T.S., U.K.B. and A.E.-J. were responsible for overseeing research activity planning and execution. T.O. and T.S. were responsible for project administration. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study (NCT05158140) was conducted in accordance with principles of Good Clinical Practice guidelines and was approved by the appropriate institutional review boards and regulatory agencies. The approach of Merck &#x00026; Co., Inc., Rahway, NJ, USA to the conduct of clinical trials is in accordance with the ethical principles that have their origin in the Declaration of Helsinki and is consistent with Good Clinical Practice and applicable regulatory requirement(s).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data sharing policy, including restrictions, of Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, NJ, USA (MSD), is available at <uri xlink:href="https://trialstransparency.msdclinicaltrials.com/policies-perspectives.aspx">https://trialstransparency.msdclinicaltrials.com/policies-perspectives.aspx</uri> (accessed on 13 February 2025). Requests for access to the clinical study data can be submitted via email to the Data Access mailbox (mailto:<email>dataaccess@msd.com</email>).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>T.O., G.T., T.M.S., L.G., T.S., M.J., N.B., U.K.B. and A.E.-J. are employees of Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, NJ, USA, and may own stock and/or hold stock options in Merck &#x00026; Co., Inc., Rahway, NJ, USA. E.P. reports serving as a principal investigator for this study. A.S.W. may own shares or stock options in Carbon Health, North Hollywood, CA, USA. S.C. and Z.E. are employees of Moderna, Inc. and may own stock/stock options in the company. Merck Sharp &#x00026; Dohme LLC, a subsidiary of Merck &#x00026; Co., Inc., Rahway, NJ, USA, was involved in the study design, collection, analysis, and interpretation of data, as well as data checking of information provided in the manuscript. However, ultimate responsibility for opinions, conclusions, and data interpretation lies with the authors.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00192"><label>1.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Active Bacterial Core Surveillance (ABCs) Report: <italic toggle="yes">Streptococcus pneumoniae</italic></article-title><year>2019</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf" ext-link-type="uri">https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B2-vaccines-13-00192"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grant</surname><given-names>L.R.</given-names></name>
<name><surname>Meche</surname><given-names>A.</given-names></name>
<name><surname>McGrath</surname><given-names>L.</given-names></name>
<name><surname>Miles</surname><given-names>A.</given-names></name>
<name><surname>Alfred</surname><given-names>T.</given-names></name>
<name><surname>Yan</surname><given-names>Q.</given-names></name>
<name><surname>Chilson</surname><given-names>E.</given-names></name>
</person-group><article-title>Risk of pneumococcal disease in US adults by age and risk profile</article-title><source>Open Forum Infect. Dis.</source><year>2023</year><volume>10</volume><fpage>ofad192</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofad192</pub-id><pub-id pub-id-type="pmid">37180598</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00192"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Leidner</surname><given-names>A.J.</given-names></name>
<name><surname>Gierke</surname><given-names>R.</given-names></name>
<name><surname>Farrar</surname><given-names>J.L.</given-names></name>
<name><surname>Morgan</surname><given-names>R.L.</given-names></name>
<name><surname>Campos-Outcalt</surname><given-names>D.</given-names></name>
<name><surname>Schechter</surname><given-names>R.</given-names></name>
<name><surname>Poehling</surname><given-names>K.A.</given-names></name>
<name><surname>Long</surname><given-names>S.S.</given-names></name>
<name><surname>Loehr</surname><given-names>J.</given-names></name>
<etal/>
</person-group><source>Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices&#x02014;United States, 2024</source><publisher-name>Centers for Disease Control and Prevention</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2024</year><fpage>793</fpage><lpage>798</lpage></element-citation></ref><ref id="B4-vaccines-13-00192"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>C.</given-names></name>
<name><surname>Anderson</surname><given-names>R.</given-names></name>
</person-group><article-title>The role of co-infections and secondary infections in patients with COVID-19</article-title><source>Pneumonia</source><year>2021</year><volume>13</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/s41479-021-00083-w</pub-id><pub-id pub-id-type="pmid">33894790</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00192"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Del Pozo</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Respiratory co-and superinfections in COVID-19</article-title><source>Rev. Esp. Quimioter.</source><year>2021</year><volume>34</volume><issue>(Suppl. 1)</issue><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.37201/req/s01.20.2021</pub-id><pub-id pub-id-type="pmid">34598432</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00192"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amin-Chowdhury</surname><given-names>Z.</given-names></name>
<name><surname>Aiano</surname><given-names>F.</given-names></name>
<name><surname>Mensah</surname><given-names>A.</given-names></name>
<name><surname>Sheppard</surname><given-names>C.L.</given-names></name>
<name><surname>Litt</surname><given-names>D.</given-names></name>
<name><surname>Fry</surname><given-names>N.K.</given-names></name>
<name><surname>Andrews</surname><given-names>N.</given-names></name>
<name><surname>Ramsay</surname><given-names>M.E.</given-names></name>
<name><surname>Ladhani</surname><given-names>S.N.</given-names></name>
</person-group><article-title>Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal Coinfection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Prospective National Cohort Study, England</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>72</volume><fpage>e65</fpage><lpage>e75</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1728</pub-id><pub-id pub-id-type="pmid">33196783</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00192"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sultana</surname><given-names>J.</given-names></name>
<name><surname>Mazzaglia</surname><given-names>G.</given-names></name>
<name><surname>Luxi</surname><given-names>N.</given-names></name>
<name><surname>Cancellieri</surname><given-names>A.</given-names></name>
<name><surname>Capuano</surname><given-names>A.</given-names></name>
<name><surname>Ferrajolo</surname><given-names>C.</given-names></name>
<name><surname>de Waure</surname><given-names>C.</given-names></name>
<name><surname>Ferlazzo</surname><given-names>G.</given-names></name>
<name><surname>Trifir&#x000f2;</surname><given-names>G.</given-names></name>
</person-group><article-title>Potential effects of vaccinations on the prevention of COVID-19: Rationale, clinical evidence, risks, and public health considerations</article-title><source>Expert Rev. Vaccines</source><year>2020</year><volume>19</volume><fpage>919</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1825951</pub-id><pub-id pub-id-type="pmid">32940090</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00192"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Im</surname><given-names>H.</given-names></name>
<name><surname>Ser</surname><given-names>J.</given-names></name>
<name><surname>Sim</surname><given-names>U.</given-names></name>
<name><surname>Cho</surname><given-names>H.</given-names></name>
</person-group><article-title>Promising expectations for pneumococcal vaccination during COVID-19</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>1507</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9121507</pub-id><pub-id pub-id-type="pmid">34960253</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00192"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newell</surname><given-names>K.</given-names></name>
<name><surname>Fischer</surname><given-names>M.</given-names></name>
<name><surname>Massey</surname><given-names>S.</given-names></name>
<name><surname>Orell</surname><given-names>L.</given-names></name>
<name><surname>Steinberg</surname><given-names>J.</given-names></name>
<name><surname>Tompkins</surname><given-names>M.</given-names></name>
<name><surname>Castrodale</surname><given-names>L.</given-names></name>
<name><surname>McLaughlin</surname><given-names>J.</given-names></name>
</person-group><article-title>Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020&#x02013;2021</article-title><source>Emerg. Infect. Dis.</source><year>2023</year><volume>29</volume><fpage>1765</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.3201/eid2909.230080</pub-id><pub-id pub-id-type="pmid">37506683</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00192"><label>10.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>Pneumococcal Vaccine Recommendations</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html" ext-link-type="uri">https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-23">(accessed on 23 January 2025)</date-in-citation></element-citation></ref><ref id="B11-vaccines-13-00192"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>M.</given-names></name>
<name><surname>Leidner</surname><given-names>A.</given-names></name>
<name><surname>Gierke</surname><given-names>R.</given-names></name>
<name><surname>Xing</surname><given-names>W.</given-names></name>
<name><surname>Accorsi</surname><given-names>E.</given-names></name>
<name><surname>Moro</surname><given-names>P.</given-names></name>
<name><surname>Kamboj</surname><given-names>M.</given-names></name>
<name><surname>Kuchel</surname><given-names>G.</given-names></name>
<name><surname>Schechter</surname><given-names>R.</given-names></name>
<name><surname>Loehr</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged &#x02265;50 Years: Recommendations of the Advisory Committee on Immunization Practices&#x02014;United States, 2024</article-title><source>MMWR</source><year>2025</year><volume>74</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7401a1</pub-id><pub-id pub-id-type="pmid">39773952</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00192"><label>12.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>Types of Pneumococcal Vaccines</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/pneumococcal/vaccines/types.html" ext-link-type="uri">https://www.cdc.gov/pneumococcal/vaccines/types.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B13-vaccines-13-00192"><label>13.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Food and Drug Administration</collab>
</person-group><article-title>PNEUMOVAX 23 Prescribing Information</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/media/80547/download" ext-link-type="uri">https://www.fda.gov/media/80547/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-04">(accessed on 4 December 2024)</date-in-citation></element-citation></ref><ref id="B14-vaccines-13-00192"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Tereziu</surname><given-names>S.</given-names></name>
<name><surname>Minter</surname><given-names>D.A.</given-names></name>
</person-group><source>Pneumococcal Vaccine</source><comment>[Internet]</comment><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year></element-citation></ref><ref id="B15-vaccines-13-00192"><label>15.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Food and Drug Administration</collab>
</person-group><article-title>VAXNEUVANCE&#x02122; (Pneumococcal 15-Valent Conjugate Vaccine) Prescribing Information</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/media/150819/download" ext-link-type="uri">https://www.fda.gov/media/150819/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B16-vaccines-13-00192"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>23-valent pneumococcal polysaccharide vaccine. WHO position paper</article-title><source>Wkly. Epidemiol. Rec.</source><year>2008</year><volume>83</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">18927997</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00192"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Chapter 17: Pneumococcal Disease</article-title><source>The Pink Book: Epidemiology and Prevention of Vaccine-Preventable Diseases</source><edition>14th ed.</edition><publisher-name>Centers for Disease Control and Prevention</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2015</year><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html" ext-link-type="uri">https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B18-vaccines-13-00192"><label>18.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Pneumococcal Polysaccharide Vaccine Information Statement</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-polysaccharide.html" ext-link-type="uri">https://www.cdc.gov/vaccines/hcp/current-vis/pneumococcal-polysaccharide.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B19-vaccines-13-00192"><label>19.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>Meeting of the Advisory Committee on Immunization Practices (ACIP)</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/faca/committees/acip.html" ext-link-type="uri">https://www.cdc.gov/faca/committees/acip.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B20-vaccines-13-00192"><label>20.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>Summary of Risk-Based Pneumococcal Vaccination Recommendations</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/risk-indications.html" ext-link-type="uri">https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/risk-indications.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B21-vaccines-13-00192"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>B.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>P.</given-names></name>
<name><surname>Shi</surname><given-names>Z.L.</given-names></name>
</person-group><article-title>Characteristics of SARS-CoV-2 and COVID-19</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>141</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-00459-7</pub-id><pub-id pub-id-type="pmid">33024307</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00192"><label>22.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Food and Drug Administration</collab>
</person-group><article-title>Emergency Use Authorization (EUA) Amendment for an Unapproved Product Review Memorandum: EUA 27073</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/media/153912/download" ext-link-type="uri">https://www.fda.gov/media/153912/download</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B23-vaccines-13-00192"><label>23.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Food and Drug Administration</collab>
</person-group><article-title>SPIKEVAX Package Insert</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/media/155675/download?attachment" ext-link-type="uri">https://www.fda.gov/media/155675/download?attachment</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B24-vaccines-13-00192"><label>24.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html" ext-link-type="uri">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B25-vaccines-13-00192"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toback</surname><given-names>S.</given-names></name>
<name><surname>Galiza</surname><given-names>E.</given-names></name>
<name><surname>Cosgrove</surname><given-names>C.</given-names></name>
<name><surname>Galloway</surname><given-names>J.</given-names></name>
<name><surname>Goodman</surname><given-names>A.L.</given-names></name>
<name><surname>Swift</surname><given-names>P.A.</given-names></name>
<name><surname>Rajaram</surname><given-names>S.</given-names></name>
<name><surname>Graves-Jones</surname><given-names>A.</given-names></name>
<name><surname>Edelman</surname><given-names>J.</given-names></name>
<name><surname>Burns</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial</article-title><source>Lancet Respir. Med.</source><year>2022</year><volume>10</volume><fpage>167</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00409-4</pub-id><pub-id pub-id-type="pmid">34800364</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00192"><label>26.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control Prevention (CDC)</collab>
</person-group><article-title>Vaccine Recommendations Guidelines of the A.C.I.P. Timing and Spacing of Immunobiologics</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html" ext-link-type="uri">https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B27-vaccines-13-00192"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bonanni</surname><given-names>P.</given-names></name>
<name><surname>Steffen</surname><given-names>R.</given-names></name>
<name><surname>Schelling</surname><given-names>J.</given-names></name>
<name><surname>Balaisyte-Jazone</surname><given-names>L.</given-names></name>
<name><surname>Posiuniene</surname><given-names>I.</given-names></name>
<name><surname>Zato&#x00144;ski</surname><given-names>M.</given-names></name>
<name><surname>Van Damme</surname><given-names>P.</given-names></name>
</person-group><article-title>Vaccine co-administration in adults: An effective way to improve vaccination coverage</article-title><source>Hum. Vaccines Immunother.</source><year>2023</year><volume>19</volume><fpage>2195786</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2195786</pub-id><pub-id pub-id-type="pmid">37039318</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00192"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harris</surname><given-names>D.A.</given-names></name>
<name><surname>Chachlani</surname><given-names>P.</given-names></name>
<name><surname>Hayes</surname><given-names>K.N.</given-names></name>
<name><surname>McCarthy</surname><given-names>E.P.</given-names></name>
<name><surname>Wen</surname><given-names>K.J.</given-names></name>
<name><surname>Deng</surname><given-names>Y.</given-names></name>
<name><surname>Zullo</surname><given-names>A.R.</given-names></name>
<name><surname>Djibo</surname><given-names>D.A.</given-names></name>
<name><surname>McMahill-Walraven</surname><given-names>C.N.</given-names></name>
<name><surname>Smith-Ray</surname><given-names>R.L.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 and influenza vaccine coadministration among older U.S. adults</article-title><source>Am. J. Prev. Med.</source><year>2024</year><volume>67</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.amepre.2024.02.013</pub-id><pub-id pub-id-type="pmid">38401746</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00192"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janssen</surname><given-names>C.</given-names></name>
<name><surname>Mosnier</surname><given-names>A.</given-names></name>
<name><surname>Gavazzi</surname><given-names>G.</given-names></name>
<name><surname>Combadi&#x000e8;re</surname><given-names>B.</given-names></name>
<name><surname>Cr&#x000e9;pey</surname><given-names>P.</given-names></name>
<name><surname>Gaillat</surname><given-names>J.</given-names></name>
<name><surname>Launay</surname><given-names>O.</given-names></name>
<name><surname>Botelho-Nevers</surname><given-names>E.</given-names></name>
</person-group><article-title>Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2131166</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2131166</pub-id><pub-id pub-id-type="pmid">36256633</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00192"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>N.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Ni</surname><given-names>J.</given-names></name>
</person-group><article-title>Effectiveness and safety of dual influenza and pneumococcal vaccination versus separate administration or no vaccination in older adults: A meta-analysis</article-title><source>Expert Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1495077</pub-id><pub-id pub-id-type="pmid">29961353</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00192"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lewnard</surname><given-names>J.A.</given-names></name>
<name><surname>Bruxvoort</surname><given-names>K.J.</given-names></name>
<name><surname>Fischer</surname><given-names>H.</given-names></name>
<name><surname>Hong</surname><given-names>V.X.</given-names></name>
<name><surname>Grant</surname><given-names>L.R.</given-names></name>
<name><surname>Jodar</surname><given-names>L.</given-names></name>
<name><surname>Gessner</surname><given-names>B.D.</given-names></name>
<name><surname>Tartof</surname><given-names>S.Y.</given-names></name>
</person-group><article-title>Prevention of coronavirus disease 2019 among older adults receiving pneumococcal conjugate vaccine suggests interactions between <italic toggle="yes">Streptococcus pneumoniae</italic> and severe acute respiratory syndrome coronavirus 2 in the respiratory tract</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>1710</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab128</pub-id><pub-id pub-id-type="pmid">33693636</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00192"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dixon</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>The International Conference on Harmonization Good Clinical Practice guideline</article-title><source>Qual. Assur.</source><year>1998</year><volume>6</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1080/105294199277860</pub-id><pub-id pub-id-type="pmid">10386329</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00192"><label>33.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Clinicaltrials.gov</collab>
</person-group><article-title>Safety, Tolerability, and Immunogenicity of V110 or V114 Co-Administered with a Booster Dose of mRNA-1273 in Healthy Adults (V110-911) (NCT05158140)</article-title><comment>Available online: <ext-link xlink:href="https://clinicaltrials.gov/study/NCT05158140?term=V110-911&#x00026;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05158140?term=V110-911&#x00026;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-01-23">(accessed on 23 January 2024)</date-in-citation></element-citation></ref><ref id="B34-vaccines-13-00192"><label>34.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Pfizer</collab>
</person-group><article-title>Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older</article-title><comment>Available online: <ext-link xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-emergency-use-authorization" ext-link-type="uri">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-emergency-use-authorization</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref><ref id="B35-vaccines-13-00192"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rosenblum</surname><given-names>H.G.</given-names></name>
<name><surname>Wallace</surname><given-names>M.</given-names></name>
<name><surname>Godfrey</surname><given-names>M.</given-names></name>
<name><surname>Roper</surname><given-names>L.E.</given-names></name>
<name><surname>Hall</surname><given-names>E.</given-names></name>
<name><surname>Fleming-Dutra</surname><given-names>K.E.</given-names></name>
<name><surname>Link-Gelles</surname><given-names>R.</given-names></name>
<name><surname>Pilishvili</surname><given-names>T.</given-names></name>
<name><surname>Williams</surname><given-names>J.</given-names></name>
<name><surname>Moulia</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title>Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines&#x02014;United States, October 2022</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2022</year><volume>71</volume><fpage>1436</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7145a2</pub-id><pub-id pub-id-type="pmid">36355612</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00192"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clopper</surname><given-names>C.J.</given-names></name>
<name><surname>Pearson</surname><given-names>E.S.</given-names></name>
</person-group><article-title>The use of confidence or fiducial limits illustrated in the case of the binomial</article-title><source>Biometrika</source><year>1934</year><volume>26</volume><fpage>404</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1093/biomet/26.4.404</pub-id></element-citation></ref><ref id="B37-vaccines-13-00192"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pattinson</surname><given-names>D.</given-names></name>
<name><surname>Jester</surname><given-names>P.</given-names></name>
<name><surname>Gu</surname><given-names>C.</given-names></name>
<name><surname>Guan</surname><given-names>L.</given-names></name>
<name><surname>Armbrust</surname><given-names>T.</given-names></name>
<name><surname>Petrie</surname><given-names>J.G.</given-names></name>
<name><surname>King</surname><given-names>J.P.</given-names></name>
<name><surname>Nguyen</surname><given-names>H.Q.</given-names></name>
<name><surname>Belongia</surname><given-names>E.A.</given-names></name>
<name><surname>Halfmann</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses</article-title><source>EBioMedicine</source><year>2024</year><volume>103</volume><elocation-id>105103</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2024.105103</pub-id><pub-id pub-id-type="pmid">38574407</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00192"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mondelli</surname><given-names>M.U.</given-names></name>
</person-group><article-title>Does co-administration of vaccines interfere with immune responses? The jury is still out</article-title><source>Clin. Microbiol. Infect.</source><year>2023</year><volume>29</volume><fpage>1482</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2023.09.022</pub-id><pub-id pub-id-type="pmid">37805030</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00192"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stacey</surname><given-names>H.L.</given-names></name>
<name><surname>Rosen</surname><given-names>J.</given-names></name>
<name><surname>Peterson</surname><given-names>J.T.</given-names></name>
<name><surname>Williams-Diaz</surname><given-names>A.</given-names></name>
<name><surname>Gakhar</surname><given-names>V.</given-names></name>
<name><surname>Sterling</surname><given-names>T.M.</given-names></name>
<name><surname>Acosta</surname><given-names>C.J.</given-names></name>
<name><surname>Nolan</surname><given-names>K.M.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Pedley</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults</article-title><source>Hum. Vaccines Immunother.</source><year>2019</year><volume>15</volume><fpage>530</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1080/21645515.2018.1532249</pub-id><pub-id pub-id-type="pmid">30648919</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00192"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>J.Y.</given-names></name>
<name><surname>Chang</surname><given-names>C.J.</given-names></name>
<name><surname>Andrews</surname><given-names>C.</given-names></name>
<name><surname>Diez-Domingo</surname><given-names>J.</given-names></name>
<name><surname>Oh</surname><given-names>M.D.</given-names></name>
<name><surname>Dagan</surname><given-names>R.</given-names></name>
<name><surname>Hartzel</surname><given-names>J.</given-names></name>
<name><surname>Pedley</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Sterling</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged &#x02265;50years: A randomized phase III trial (PNEU-PATH)</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>6422</fpage><lpage>6436</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.08.038</pub-id><pub-id pub-id-type="pmid">34489128</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00192"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buchwald</surname><given-names>U.K.</given-names></name>
<name><surname>Andrews</surname><given-names>C.P.</given-names></name>
<name><surname>Ervin</surname><given-names>J.</given-names></name>
<name><surname>Peterson</surname><given-names>J.T.</given-names></name>
<name><surname>Tamms</surname><given-names>G.M.</given-names></name>
<name><surname>Krupa</surname><given-names>D.</given-names></name>
<name><surname>Ajiboye</surname><given-names>P.</given-names></name>
<name><surname>Roalfe</surname><given-names>L.</given-names></name>
<name><surname>Krick</surname><given-names>A.L.</given-names></name>
<name><surname>Sterling</surname><given-names>T.M.</given-names></name>
<etal/>
</person-group><article-title>Sequential administration of Prevnar 13 and PNEUMOVAX 23 in healthy participants 50 years of age and older</article-title><source>Hum. Vaccines Immunother.</source><year>2021</year><volume>17</volume><fpage>2678</fpage><lpage>2690</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1888621</pub-id><pub-id pub-id-type="pmid">34019468</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00192"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>L.</given-names></name>
<name><surname>Vrbicky</surname><given-names>K.</given-names></name>
<name><surname>Montefiori</surname><given-names>D.</given-names></name>
<name><surname>Huang</surname><given-names>W.</given-names></name>
<name><surname>Nestorova</surname><given-names>B.</given-names></name>
<name><surname>Chang</surname><given-names>Y.</given-names></name>
<name><surname>Carfi</surname><given-names>A.</given-names></name>
<name><surname>Edwards</surname><given-names>D.K.</given-names></name>
<name><surname>Oestreicher</surname><given-names>J.</given-names></name>
<name><surname>Legault</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Immune response to SARS-CoV-2 after a booster of mRNA-1273: An open-label phase 2 trial</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1042</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01739-w</pub-id><pub-id pub-id-type="pmid">35241844</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00192"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baden</surname><given-names>L.R.</given-names></name>
<name><surname>El Sahly</surname><given-names>H.M.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Follmann</surname><given-names>D.</given-names></name>
<name><surname>Hachigian</surname><given-names>G.</given-names></name>
<name><surname>Strout</surname><given-names>C.</given-names></name>
<name><surname>Overcash</surname><given-names>J.S.</given-names></name>
<name><surname>Doblecki-Lewis</surname><given-names>S.</given-names></name>
<name><surname>Whitaker</surname><given-names>J.A.</given-names></name>
<name><surname>Anderson</surname><given-names>E.J.</given-names></name>
<etal/>
</person-group><article-title>Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>7469</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-50376-z</pub-id><pub-id pub-id-type="pmid">39209823</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00192"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fitz-Patrick</surname><given-names>D.</given-names></name>
<name><surname>Young</surname><given-names>M.</given-names></name>
<name><surname>Yacisin</surname><given-names>K.</given-names></name>
<name><surname>McElwee</surname><given-names>K.</given-names></name>
<name><surname>Belanger</surname><given-names>T.</given-names></name>
<name><surname>Belanger</surname><given-names>K.</given-names></name>
<name><surname>Peng</surname><given-names>Y.</given-names></name>
<name><surname>Lee</surname><given-names>D.Y.</given-names></name>
<name><surname>Gruber</surname><given-names>W.C.</given-names></name>
<name><surname>Scott</surname><given-names>D.A.</given-names></name>
<etal/>
</person-group><article-title>Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults &#x02265;65 years old</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>4190</fpage><lpage>4198</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.05.002</pub-id><pub-id pub-id-type="pmid">37244809</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00192"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lazarus</surname><given-names>R.</given-names></name>
<name><surname>Baos</surname><given-names>S.</given-names></name>
<name><surname>Cappel-Porter</surname><given-names>H.</given-names></name>
<name><surname>Carson-Stevens</surname><given-names>A.</given-names></name>
<name><surname>Clout</surname><given-names>M.</given-names></name>
<name><surname>Culliford</surname><given-names>L.</given-names></name>
<name><surname>Emmett</surname><given-names>S.R.</given-names></name>
<name><surname>Garstang</surname><given-names>J.</given-names></name>
<name><surname>Gbadamoshi</surname><given-names>L.</given-names></name>
<name><surname>Hallis</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2277</fpage><lpage>2287</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02329-1</pub-id><pub-id pub-id-type="pmid">34774197</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00192"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Izikson</surname><given-names>R.</given-names></name>
<name><surname>Brune</surname><given-names>D.</given-names></name>
<name><surname>Bolduc</surname><given-names>J.S.</given-names></name>
<name><surname>Bourron</surname><given-names>P.</given-names></name>
<name><surname>Fournier</surname><given-names>M.</given-names></name>
<name><surname>Moore</surname><given-names>T.M.</given-names></name>
<name><surname>Pandey</surname><given-names>A.</given-names></name>
<name><surname>Perez</surname><given-names>L.</given-names></name>
<name><surname>Sater</surname><given-names>N.</given-names></name>
<name><surname>Shrestha</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged &#x02265;65 years: A phase 2, randomised, open-label study</article-title><source>Lancet Respir. Med.</source><year>2022</year><volume>10</volume><fpage>392</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00557-9</pub-id><pub-id pub-id-type="pmid">35114141</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00192"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chalkias</surname><given-names>S.</given-names></name>
<name><surname>Harper</surname><given-names>C.</given-names></name>
<name><surname>Vrbicky</surname><given-names>K.</given-names></name>
<name><surname>Walsh</surname><given-names>S.R.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Brosz</surname><given-names>A.</given-names></name>
<name><surname>McGhee</surname><given-names>N.</given-names></name>
<name><surname>Tomassini</surname><given-names>J.E.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Chang</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>A bivalent Omicron-containing booster vaccine against Covid-19</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>1279</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2208343</pub-id><pub-id pub-id-type="pmid">36112399</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00192"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chalkias</surname><given-names>S.</given-names></name>
<name><surname>Whatley</surname><given-names>J.L.</given-names></name>
<name><surname>Eder</surname><given-names>F.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Khetan</surname><given-names>S.</given-names></name>
<name><surname>Bradley</surname><given-names>P.</given-names></name>
<name><surname>Brosz</surname><given-names>A.</given-names></name>
<name><surname>McGhee</surname><given-names>N.</given-names></name>
<name><surname>Tomassini</surname><given-names>J.E.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: Phase 2/3 trial interim results</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2325</fpage><lpage>2333</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02517-y</pub-id><pub-id pub-id-type="pmid">37653342</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00192"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chalkias</surname><given-names>S.</given-names></name>
<name><surname>McGhee</surname><given-names>N.</given-names></name>
<name><surname>Whatley</surname><given-names>J.L.</given-names></name>
<name><surname>Essink</surname><given-names>B.</given-names></name>
<name><surname>Brosz</surname><given-names>A.</given-names></name>
<name><surname>Tomassini</surname><given-names>J.E.</given-names></name>
<name><surname>Girard</surname><given-names>B.</given-names></name>
<name><surname>Edwards</surname><given-names>D.K.</given-names></name>
<name><surname>Wu</surname><given-names>K.</given-names></name>
<name><surname>Nasir</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Interim report of the reactogenicity and immunogenicity of severe acute respiratory syndrome coronavirus 2 XBB-containing vaccines</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>230</volume><fpage>e279</fpage><lpage>e286</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiae067</pub-id><pub-id pub-id-type="pmid">38349280</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00192"><label>50.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Center for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>Vaccine Recommendations and Guidelines of the ACIP&#x02014;Special Situations</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/vaccines/hcp/imz-best-practices/special-situations.html" ext-link-type="uri">https://www.cdc.gov/vaccines/hcp/imz-best-practices/special-situations.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-26">(accessed on 26 November 2024)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00192-f001"><label>Figure 1</label><caption><p>Study design. AE: adverse event; AESI: adverse event of special interest; eVRC: electronic vaccination report card; mRNA-1273: monovalent mRNA COVID-19 vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PE: physical examination; PPSV23: 23-valent pneumococcal polysaccharide vaccine; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p></caption><graphic xlink:href="vaccines-13-00192-g001" position="float"/></fig><fig position="float" id="vaccines-13-00192-f002"><label>Figure 2</label><caption><p>CONSORT flow diagram. Each participant was counted once. Two participants received study interventions other than what they were randomized to receive. In the PPSV23 concomitant group, one participant received two doses of mRNA-1273 at the first study visit. In the PCV15 concomitant group, one participant received PPSV23 and mRNA-1273 at the first study visit. Enrollment was closed on 31 August 2022, following EUA of the bivalent COVID-19 vaccine boosters and revocation of the EUA for monovalent COVID-19 vaccine boosters. At the time enrollment was closed, 850 participants were enrolled. As of the final database lock, 850 participants were randomized. COVID-19: coronavirus disease 2019; EUA: emergency use authorization; mRNA-1273: monovalent mRNA COVID-19 vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.</p></caption><graphic xlink:href="vaccines-13-00192-g002" position="float"/></fig><fig position="float" id="vaccines-13-00192-f003"><label>Figure 3</label><caption><p>Participants with solicited AEs (incidence &#x0003e;0% in one or more group) in the all-participants-as-treated population following any vaccination. Every participant was counted a single time for each AE. Injection-site erythema, injection-site pain, injection-site swelling, lymphadenopathy, arthralgia, fatigue, headache, myalgia, nausea, vomiting, and chills were solicited from Day 1 to Day 7 following vaccination. MedDRA version 26.0 was used. AE: adverse event; MedDRA: Medical Dictionary for Regulatory Activities; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.</p></caption><graphic xlink:href="vaccines-13-00192-g003" position="float"/></fig><table-wrap position="float" id="vaccines-13-00192-t001"><object-id pub-id-type="pii">vaccines-13-00192-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics and demographics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Participants in Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PPSV23 Concomitant Group<break/>(n = 214)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PPSV23 Sequential Group <break/>(n = 211)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCV15 Concomitant Group<break/>(n = 210)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCV15 Sequential Group<break/>(n = 208)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Sex, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">80 (37.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (46.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (37.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (50.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">131 (62.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">112 (53.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">130 (62.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Mean age, years (range)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">60.5 (50&#x02013;93)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.5 (50&#x02013;89)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.5 (50&#x02013;88)</td><td align="center" valign="middle" rowspan="1" colspan="1">60.4 (50&#x02013;86)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Age category</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">50&#x02013;64 years</td><td align="center" valign="middle" rowspan="1" colspan="1">158 (73.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">155 (73.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">153 (72.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">153 (73.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">65&#x02013;74 years</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (19.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (19.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (20.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (20.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&#x02265;75 years</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (7.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (6.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (6.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (5.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Race, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">White</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (76.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">173 (82.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">163 (77.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">157 (75.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Black or African American</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (19.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (15.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (17.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (19.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (3.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multiple</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (2.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (2.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">American Indian or Alaska Native</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Ethnicity, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Not Hispanic or Latino</td><td align="center" valign="middle" rowspan="1" colspan="1">127 (59.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">111 (52.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">122 (58.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (55.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hispanic or Latino</td><td align="center" valign="middle" rowspan="1" colspan="1">87 (40.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">98 (46.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">88 (41.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">91 (43.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Prior medications, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">At least one prior medication</td><td align="center" valign="middle" rowspan="1" colspan="1">154 (72.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">162 (76.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">160 (76.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">148 (71.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No prior medication</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (28.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (23.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (23.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (28.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Prior vaccinations, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">At least one prior vaccination</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5) <sup>&#x02020;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5) <sup>&#x02021;</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No prior vaccinations</td><td align="center" valign="middle" rowspan="1" colspan="1">214 (100.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">210 (99.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">209 (99.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">208 (100.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Concomitant medications, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">At least one concomitant medication</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (76.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">173 (82.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">167 (79.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">162 (77.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No concomitant medications</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (23.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (18.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (20.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (22.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Concomitant vaccinations, n (%)</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">At least one concomitant vaccination</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (3.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No concomitant vaccinations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210 (98.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">210 (99.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">203 (96.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">204 (98.1)</td></tr></tbody></table><table-wrap-foot><fn><p>Each participant is counted once per parameter. <sup>&#x02020;</sup> A participant in the PPSV23 sequential group had previously received an inactivated vaccine for influenza. <sup>&#x02021;</sup> A participant in the PCV15 concomitant group had previously received a vaccine for tetanus. PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00192-t002"><object-id pub-id-type="pii">vaccines-13-00192-t002_Table 2</object-id><label>Table 2</label><caption><p>Primary immunogenicity endpoint: serotype-specific OPA responses at 30 days post-vaccination.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PPSV23 Concomitant Group<break/>(n = 214)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PPSV23 Sequential Group <break/>(n = 211)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PCV15 Concomitant Group <break/>(n = 211)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">PCV15 Sequential Group <break/>(n = 211)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumococcal Serotype</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observed Response (95% CI) <sup>&#x02020;</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observed Response (95% CI) <sup>&#x02020;</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observed Response (95% CI) <sup>&#x02020;</sup></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observed Response (95% CI) <sup>&#x02020;</sup></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">182</td><td align="center" valign="middle" rowspan="1" colspan="1">236.0 (177.0&#x02013;314.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">177</td><td align="center" valign="middle" rowspan="1" colspan="1">253.5 (188.4&#x02013;341.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">186</td><td align="center" valign="middle" rowspan="1" colspan="1">208.3 (160.8&#x02013;269.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">174</td><td align="center" valign="middle" rowspan="1" colspan="1">265.6 (203.4&#x02013;346.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">167</td><td align="center" valign="middle" rowspan="1" colspan="1">174.3 (138.6&#x02013;219.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">164</td><td align="center" valign="middle" rowspan="1" colspan="1">284.0 (224.1&#x02013;359.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">174</td><td align="center" valign="middle" rowspan="1" colspan="1">237.5 (197.5&#x02013;285.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">155</td><td align="center" valign="middle" rowspan="1" colspan="1">338.4 (275.3&#x02013;416.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">182</td><td align="center" valign="middle" rowspan="1" colspan="1">1384.5 (1110.7&#x02013;1725.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">165</td><td align="center" valign="middle" rowspan="1" colspan="1">1704.4 (1370.6&#x02013;2119.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">181</td><td align="center" valign="middle" rowspan="1" colspan="1">1586.0 (1296.5&#x02013;1940.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">176</td><td align="center" valign="middle" rowspan="1" colspan="1">1758.6 (1419.4&#x02013;2178.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">189</td><td align="center" valign="middle" rowspan="1" colspan="1">423.4 (324.9&#x02013;551.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">181</td><td align="center" valign="middle" rowspan="1" colspan="1">376.3 (282.6&#x02013;501.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">190</td><td align="center" valign="middle" rowspan="1" colspan="1">447.0 (341.7&#x02013;584.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">180</td><td align="center" valign="middle" rowspan="1" colspan="1">505.5 (382.7&#x02013;667.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013;</td><td align="center" valign="middle" rowspan="1" colspan="1">176</td><td align="center" valign="middle" rowspan="1" colspan="1">4345.3 (3490.0&#x02013;5410.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">162</td><td align="center" valign="middle" rowspan="1" colspan="1">5787.1 (4468.4&#x02013;7495.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6B</td><td align="center" valign="middle" rowspan="1" colspan="1">182</td><td align="center" valign="middle" rowspan="1" colspan="1">1336.7 (1038.2&#x02013;1721.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">171</td><td align="center" valign="middle" rowspan="1" colspan="1">1326.8 (1016.7&#x02013;1731.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">173</td><td align="center" valign="middle" rowspan="1" colspan="1">3655.5 (2939.1&#x02013;4546.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">158</td><td align="center" valign="middle" rowspan="1" colspan="1">4992.9 (3896.2&#x02013;6398.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7F</td><td align="center" valign="middle" rowspan="1" colspan="1">184</td><td align="center" valign="middle" rowspan="1" colspan="1">2614.4 (2123.8&#x02013;3218.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">174</td><td align="center" valign="middle" rowspan="1" colspan="1">2420.2 (1919.6&#x02013;3051.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">187</td><td align="center" valign="middle" rowspan="1" colspan="1">3465.7 (2858.7&#x02013;4201.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">170</td><td align="center" valign="middle" rowspan="1" colspan="1">3283.0 (2664.3&#x02013;4045.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9V</td><td align="center" valign="middle" rowspan="1" colspan="1">185</td><td align="center" valign="middle" rowspan="1" colspan="1">1651.1 (1352.0&#x02013;2016.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">174</td><td align="center" valign="middle" rowspan="1" colspan="1">1809.2 (1502.2&#x02013;2179.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">187</td><td align="center" valign="middle" rowspan="1" colspan="1">1730.3 (1432.7&#x02013;2089.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">166</td><td align="center" valign="middle" rowspan="1" colspan="1">2026.6 (1651.0&#x02013;2487.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">184</td><td align="center" valign="middle" rowspan="1" colspan="1">3048.3 (2429.0&#x02013;3825.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">176</td><td align="center" valign="middle" rowspan="1" colspan="1">2618.4 (2078.8&#x02013;3298.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">186</td><td align="center" valign="middle" rowspan="1" colspan="1">2487.2 (2026.1&#x02013;3053.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">177</td><td align="center" valign="middle" rowspan="1" colspan="1">2460.8 (2018.4&#x02013;3000.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18C</td><td align="center" valign="middle" rowspan="1" colspan="1">188</td><td align="center" valign="middle" rowspan="1" colspan="1">1592.9 (1281.0&#x02013;1980.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">179</td><td align="center" valign="middle" rowspan="1" colspan="1">2033.7 (1639.6&#x02013;2522.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">187</td><td align="center" valign="middle" rowspan="1" colspan="1">3144.5 (2597.3&#x02013;3806.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">171</td><td align="center" valign="middle" rowspan="1" colspan="1">3183.5 (2587.9&#x02013;3916.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19A</td><td align="center" valign="middle" rowspan="1" colspan="1">185</td><td align="center" valign="middle" rowspan="1" colspan="1">2135.7 (1761.7&#x02013;2589.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">169</td><td align="center" valign="middle" rowspan="1" colspan="1">2626.1 (2139.6&#x02013;3223.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">173</td><td align="center" valign="middle" rowspan="1" colspan="1">3214.3 (2735.5&#x02013;3776.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">162</td><td align="center" valign="middle" rowspan="1" colspan="1">4037.4 (3234.4&#x02013;5039.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19F</td><td align="center" valign="middle" rowspan="1" colspan="1">180</td><td align="center" valign="middle" rowspan="1" colspan="1">1379.9 (1144.4&#x02013;1663.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">167</td><td align="center" valign="middle" rowspan="1" colspan="1">1532.6 (1250.5&#x02013;1878.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">182</td><td align="center" valign="middle" rowspan="1" colspan="1">1742.0 (1440.1&#x02013;2107.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">164</td><td align="center" valign="middle" rowspan="1" colspan="1">1950.1 (1592.9&#x02013;2387.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22F</td><td align="center" valign="middle" rowspan="1" colspan="1">175</td><td align="center" valign="middle" rowspan="1" colspan="1">2023.0 (1559.4&#x02013;2624.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">170</td><td align="center" valign="middle" rowspan="1" colspan="1">2178.4 (1630.9&#x02013;2909.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">175</td><td align="center" valign="middle" rowspan="1" colspan="1">2282.7 (1804.7&#x02013;2887.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">156</td><td align="center" valign="middle" rowspan="1" colspan="1">2670.6 (2062.6&#x02013;3457.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23F</td><td align="center" valign="middle" rowspan="1" colspan="1">183</td><td align="center" valign="middle" rowspan="1" colspan="1">739.0 (559.4&#x02013;976.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">169</td><td align="center" valign="middle" rowspan="1" colspan="1">839.9 (639.5&#x02013;1103.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">181</td><td align="center" valign="middle" rowspan="1" colspan="1">2326.3 (1831.2&#x02013;2955.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">169</td><td align="center" valign="middle" rowspan="1" colspan="1">2212.0 (1685.3&#x02013;2903.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">176</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,089.0 (7799.0&#x02013;13,051.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10,909.2 (8634.0&#x02013;13,783.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">175</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6788.5 (5312.9&#x02013;8673.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9339.7 (7330.9&#x02013;11,899.0)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>&#x02020;</sup> The within-group 95% CIs are obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. n = number of participants contributing to the analysis. Note: Post-vaccination = 30 days following vaccination with PPSV23 or PCV15 (Day 30 for PPSV23 or PCV15 concomitant groups and Day 60 for PPSV23 or PCV15 sequential groups). CI: confidence interval; OPA: opsonophagocytic activity; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00192-t003"><object-id pub-id-type="pii">vaccines-13-00192-t003_Table 3</object-id><label>Table 3</label><caption><p>Primary immunogenicity endpoint: summary of SARS-CoV-2-specific binding antibody GMTs responses with mRNA-1273.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observed GMT Response (Baseline), <break/>1/dil (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observed GMT Response, <break/>1/dil (95% CI)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GMFR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">% &#x02265;4-Fold Rise</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">PPSV23 concomitant group <break/>(N = 214)</td><td align="center" valign="middle" rowspan="1" colspan="1">203</td><td align="center" valign="middle" rowspan="1" colspan="1">96,219.3 <break/>(74,340.0&#x02013;124,538.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">197</td><td align="center" valign="middle" rowspan="1" colspan="1">824,118.4<break/>(717,446.4&#x02013;946,650.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">196</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6 <break/>(6.7&#x02013;11.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">196</td><td align="center" valign="middle" rowspan="1" colspan="1">55.1 <break/>(47.9&#x02013;62.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PCV15 concomitant group<break/>(N = 210)</td><td align="center" valign="middle" rowspan="1" colspan="1">201</td><td align="center" valign="middle" rowspan="1" colspan="1">104,885.7 <break/>(80,862.2&#x02013;136,046.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">196</td><td align="center" valign="middle" rowspan="1" colspan="1">861,746.4<break/>(756,496.4&#x02013;981,639.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">195</td><td align="center" valign="middle" rowspan="1" colspan="1">8.1 <break/>(6.4&#x02013;10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">195</td><td align="center" valign="middle" rowspan="1" colspan="1">52.3 <break/>(45.1&#x02013;59.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPSV23 and PCV15 sequential groups<break/>(N = 419)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">403</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">115,174.3 <break/>(96,328.9&#x02013;137,706.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">382</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,102,295.7<break/>(1,003,694.1&#x02013;1,210,583.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">379</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.1 <break/>(7.7&#x02013;10.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">379</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.9 <break/>(50.8&#x02013;61.0)</td></tr></tbody></table><table-wrap-foot><fn><p>CI: confidence interval; GMFR: geometric mean fold rise; GMT: geometric mean titer; N: number of participants randomized and vaccinated; n: number of participants contributing to the analysis; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00192-t004"><object-id pub-id-type="pii">vaccines-13-00192-t004_Table 4</object-id><label>Table 4</label><caption><p>Safety summary.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Participants in Population, n (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PPSV23 Concomitant Group<break/>(n = 214)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PPSV23 Sequential Group<break/>(n = 211)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCV15 Concomitant Group<break/>(n = 209)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCV15 Sequential Group<break/>(n = 208)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>At least one AE</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">175 (81.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">171 (81.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (78.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">174 (83.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Injection-site</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (76.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">162 (76.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">154 (73.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (78.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Systemic</td><td align="center" valign="middle" rowspan="1" colspan="1">132 (61.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">123 (58.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">121 (57.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">132 (63.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>No AEs reported</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (18.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (19.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (21.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (16.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Vaccine-related AEs&#x000a0;<sup>&#x02020;</sup>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">171 (79.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">170 (80.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (78.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">172 (82.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Injection-site</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (76.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">162 (76.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">154 (73.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">164 (78.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Systemic</td><td align="center" valign="middle" rowspan="1" colspan="1">119 (55.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">108 (51.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">111 (53.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (59.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>At least one solicited AE</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">171 (79.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">170 (80.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">163 (78.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">171 (82.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>At least one systemic AE</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Following vaccination 1</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (57.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">227 (54.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">111 (53.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">227 (54.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Following vaccination 2</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (20.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (25.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (20.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (39.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>At least one systemic vaccine-related AE&#x000a0;<sup>&#x02020;</sup>
</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">119 (55.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">108 (51.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">111 (53.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (59.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>SAEs</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Serious vaccine-related AEs</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Deaths</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>AEs leading to discontinuation</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Vaccine-related AEs leading to discontinuation</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>SAEs leading to discontinuation</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Serious vaccine-related AEs leading to discontinuation</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0.0)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>&#x02020;</sup> Vaccine-related systemic AEs cannot be attributed to a specific vaccine following vaccination 1. MedDRA version 26.0 was used. AE: adverse event; MedDRA: Medical Dictionary for Regulatory Activities; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; SAE: serious adverse event.</p></fn></table-wrap-foot></table-wrap></floats-group></article>